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Manuscript: 
A two-week old infant was transferred to our renal ward from a district general  
neonatal intensive care unit following concerns of extreme acid-base and electrolyte 
disturbance from birth. The patient was born following spontaneous delivery at 32 
weeks gestation. Severe polyhydramnios was noted antenatally and required two 
amniocenteses, removing a total of 6L fluid. She is the third child of consanguineous 
parents, with no significant medical problems reported in her siblings.  
 
Initial investigations revealed a marked alkalosis: serum bicarbonate was 81mmol/L 
with a venous pH of 7.8. Biochemistry revealed a sodium of 116 mmol/L, potassium 
of 2.1 mmol, chloride of 59mmol/L and calcium of 1.99mmol/L. The patient 
demonstrated evdience of renal impairment with a urea of 20.8mmol/L and 
creatinine 146μmol/L. Examination was normal, except for a systolic ejection 
murmur. Subsequent echocardiography was unremarkable. Polyuria had been noted 
and the patient had been managed on fluid volumes of up to 200ml/kg/day prior to 
transfer. Weight was 1.68 kg (9th percentile), length: 44 cm (25thpercentile) and head 
circumference 29 cm (5th percentile), blood pressure was normal at 68 mmHg 
systolic.  
 
Given the constellation of hypokalaemic, hypochloraemic metabolic alkalosis, a 
presumptive diagnosis of Bartter syndrome was made. Electrolyte supplementation 
with sodium and potassium totaling 14 mmol/kg/day and 13 mmol/kg/day was 
provided. Despite this the patient had a persistent severe alkalosis (pH 7.56-7.92). 
Concerns regarding her respiratory drive were initially raised in the first week of her 
admission, when she remained apneic after general anesthesia for a central line 
insertion and needed mechanical ventilation for 24 hours. In the first few months of 
life, the patient was noted to have repeated desaturations and subsequent 
polysomnography demonstrated prolonged periods of cyclical dips (73 dips/hour; 
normal <5) in oxygen saturation (SpO2, see figure 1): with a mean and absolute nadir 
of 88% and 77%, respectively. Mean transcutaneous pCO2 was raised at 75mmHg 
(10kPa), maximum 80mmHg, and a respiratory rate of 10 in periodic breathing, rising 
to 48 breaths/minute in Quiet Sleep. The Apnoea-Hypopnoea Index, a ratio of apneic 
episodes during hours slept, was 68 central events/hour (normal 0-4).  
 
The patient remained polyuric with a urine output of 8-10ml/kg/h, leading to 
frequent episodes of dehydration with associated acute kidney injury (AKI). The 
highest recorded sodium was 176mmol/L, which improved with intravenous 
replacement of salt and water. Prostaglandin synthesis inhibitors, first indomethacin 
then celecoxib were trialed, but with minimal improvement and had to be frequently 
halted during episodes of AKI. Enteral feeds and salt supplementation were at times 
poorly tolerated and on one occasion led to hyponatraemic seizures (recorded 
sodium 94mmol/L).  
 
Over the following year, she demonstrated profound global developmental delay 
with associated microcephaly and sensorineural hearing loss (confirmed by 
otoacoustic emissions and auditory brainstem response testing). She had evidence 
of chronic renal impairment from birth with an estimated GFR around 
30ml/min/1.73m2. The patient also developed severe hypophosphataemic rickets, 
with plasma phosphate levels as low as 0.30 mmol/l, alkaline phosphatase levels as 
high as 1226 U/l (normal 80-345) and renal phosphate wasting 
(TmP/GFR<0.83mmol/l; normal 1.10-2.70). 
  
Given the serious clinical difficulties, which were chiefly attributed to the severe 
alkalosis, discussions were held about potential treatment approaches, including 
palliative care, bilateral nephrectomies with consequent renal replacement 
treatment, as well as titration with hydrochloric acid. At 10 months of age, a trial of 
amiloride was decided with the parents and the drug was slowly increased to 
1mg/kg/day. Within weeks, plasma bicarbonate levels decreased to between 27-47 
mmol/L, pH levels were persistently below 7.6, the patient’s desaturations were less 
frequent, plasma phosphate levels normalized without supplementation and an 
improvement in general alertness was noted.  
 
The patient was eventually discharged home after her first birthday, albeit with 
continuous jejunal feeds. She has shown some development, but remains severely 
delayed. Bloods at last follow-up reveal a serum bicarbonate of 31mmol/L (venous 
pH 7.54), potassium 4.0mmol/L, chloride 91mmol/L and creatinine of 86μmol/L. 
Genetic testing confirmed Bartter syndrome type IV with a homozygous 1bp deletion 
in BSND (p.Pro151Leufs*27).  
 
Bartter syndrome is a genetically heterogeneous condition characterized by failure 
of renal reabsorption of sodium and chloride in the thick ascending limb of Henle’s 
loop, leading to insensible salt and water loss with consequent secondary 
hyperaldosteronism1. It is the increased mineralocorticoid activity that leads to the 
characteristic electrolyte profile of hypokalaemic metabolic alkalosis by enhancing 
potassium and proton secretion in the collecting duct in exchange for sodium 
reabsorption. Bartter syndrome type IV is caused by mutations in the BSND gene 
encoding Barttin, an essential subunit of the chloride channels CICNKA and CICNKB 
expressed in the loop of Henle, distal convoluted tubule and inner ear1. Mutations in 
CLCNKB are the cause of Bartter syndrome type 3, typically of postnatal onset and 
without hearing loss, the so-called ‘classic’ Bartter syndrome. This milder 
presentation is presumably due to compensation by CLCNKA. In contrast, Bartter 
syndrome type IV is typically associated with a severe renal phenotype as well as 
hearing loss, as Barttin is a necessary subunit for both channels1. The severity of 
metabolic derangement seen in this patient yet is even more pronounced than what 
has been reported before for this condition. 
 
Metabolic alkalosis carries significant mortality: in adults, an arterial pH >7.55 is 
associated with a mortality rate of 45%, which rises to 80% if >7.65 2. Human studies 
have demonstrated a linear relationship between PaCO2 and plasma bicarbonate. 
Respiratory suppression is the physiological response to alkalosis, an effect manifest 
through reduction in tidal volume. Ventilatory resposnse to CO2 is also blunted in 
metabolic alkalosis3. 
 
The clinical finding of renal phosphate wasting leading to rickets has, to our 
knowledge, not been reported before as a complication of alkalosis in humans. Yet 
causality is likely, as renal phosphate wasting resolved with improved pH and 
involved transporters are known to be pH dependent as phosphaturia due to 
alkalosis has been demonstrated in dogs4. Metabolic alkalosis has also been shown 
to depress plasma phosphorus levels in humans, although to a lesser degree than 
respiratory alkalosis5.  
 
Most enzyme systems in our body are dependent on tight regulation of acid-base 
homoeostasis and we presume that the initial obtunded state of our patient was also 
related to the extreme alkalosis, as it improved when venous pH levels decreased. 
Developmental delay is seen in neonatal Bartter phenotypes, which may in this case, 
have been compounded by the patient’s prematurity, recurrent electrolyte 
instability, and episodes of acute on chronic kidney injury. 
 
The treatment of Bartter syndrome with potassium-sparing diuretics, such as 
amiloride is potentially hazardous, as the mineralocorticoid activation is seen as a 
critical compensatory mechanism to minimise salt losses. Given that the kidneys 
regulate volume homoeostasis through tubular salt handling, the mineralocorticoid-
induced secretion of potassium and protons can be interpreted as the evolutionary 
primate of volume over acid-base and potassium homoeostasis6. Given the severity 
of complications from the extreme alkalosis, we carefully commenced amiloride at a 
very low dose with subsequent up-titration, with close observation and concomitant 
sodium supplementation of more than 10mmol/kg/d to maintain volume 
homoeostasis. 
 
This case highlights the importance of the kidneys in maintaining homoeostasis and 
the severe consequences for whole body physiology, if the underlying molecular 
mechanism is disrupted.  
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